Alimentary Pharmacology and Therapeutics, volume 47, issue 12, pages 1597-1609

Systematic review: safety of mesalazine in ulcerative colitis

Publication typeJournal Article
Publication date2018-05-03
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor7.6
ISSN02692813, 13652036
Pharmacology (medical)
Gastroenterology
Hepatology
Abstract
Mesalazine is the most commonly prescribed medication for mild to moderate ulcerative colitis. It is generally well tolerated with some reported side effects.To summarise adverse drug events to mesalazine and recommend techniques for management. Furthermore, to determine if there is a dose-dependent relationship between high (>2.4 g/day) vs low dosing (≤2.4 g/day) and occurrence of adverse drug events.A literature search for relevant studies from inception to 1 December 2017 of the MEDLINE database was conducted. Two reviewers screened all titles identified. Data obtained from randomised controlled trials was used to estimate incidence rates of each adverse event. Two reviewers independently assessed methodological risk of bias and performed data extraction.3581 articles were initially considered. Of these, 3573 were screened, 622 reviewed and 91 included. Adverse events attributed to mesalazine included inflammatory reactions, pancreatitis, cardiotoxicity, hepatotoxicity, musculoskeletal complaints, respiratory symptoms, nephropathies and sexual dysfunction. There does not appear to be a dose-dependent relationship of mesalazine and occurrence of adverse events.Patients on mesalazine should be monitored for worsening of ulcerative colitis and development of new onset organ dysfunction. High-dose mesalazine appears to have similar safety profile as low dose, and is not associated with greater risk of adverse events. Prior to placing a patient on mesalazine, baseline liver and renal function should be evaluated. Renal function should be periodically assessed, whereas other testing should be performed depending on development of symptoms.

Top-30

Citations by journals

1
2
3
4
5
Frontiers in Pharmacology
5 publications, 5.05%
Evidence-based Complementary and Alternative Medicine
4 publications, 4.04%
International Journal of Molecular Sciences
3 publications, 3.03%
Molecules
3 publications, 3.03%
Phytomedicine
3 publications, 3.03%
Expert Review of Clinical Immunology
2 publications, 2.02%
World Journal of Hepatology
2 publications, 2.02%
Inflammopharmacology
2 publications, 2.02%
Alimentary Pharmacology and Therapeutics
2 publications, 2.02%
Journal of Crohn's and Colitis
2 publications, 2.02%
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
2 publications, 2.02%
Foods
2 publications, 2.02%
ACS applied materials & interfaces
1 publication, 1.01%
Experimental and Therapeutic Medicine
1 publication, 1.01%
Medicine (United States)
1 publication, 1.01%
European Journal of Gastroenterology and Hepatology
1 publication, 1.01%
Cartilage
1 publication, 1.01%
Pharmaceutics
1 publication, 1.01%
Nanomaterials
1 publication, 1.01%
Frontiers in Genetics
1 publication, 1.01%
Frontiers in Nutrition
1 publication, 1.01%
Frontiers in Pediatrics
1 publication, 1.01%
Frontiers in Immunology
1 publication, 1.01%
Digestive Diseases and Sciences
1 publication, 1.01%
Advances in Therapy
1 publication, 1.01%
Nature Reviews Gastroenterology and Hepatology
1 publication, 1.01%
Journal of Gastroenterology
1 publication, 1.01%
Current Microbiology
1 publication, 1.01%
Current Gastroenterology Reports
1 publication, 1.01%
1
2
3
4
5

Citations by publishers

2
4
6
8
10
12
14
16
Springer Nature
16 publications, 16.16%
Elsevier
15 publications, 15.15%
Multidisciplinary Digital Publishing Institute (MDPI)
12 publications, 12.12%
Frontiers Media S.A.
9 publications, 9.09%
Taylor & Francis
6 publications, 6.06%
Wiley
6 publications, 6.06%
Hindawi Limited
6 publications, 6.06%
Baishideng Publishing Group
4 publications, 4.04%
Oxford University Press
4 publications, 4.04%
American Chemical Society (ACS)
2 publications, 2.02%
Wolters Kluwer Health
2 publications, 2.02%
BMJ
2 publications, 2.02%
Korean Society of Gastroenterology
2 publications, 2.02%
Spandidos Publications
1 publication, 1.01%
SAGE
1 publication, 1.01%
Obsidiana Editores
1 publication, 1.01%
Dove Medical Press
1 publication, 1.01%
Gastroenterological Scientific Society of Russia
1 publication, 1.01%
Russian Phthisiologists’ Society
1 publication, 1.01%
American Physiological Society
1 publication, 1.01%
Public Library of Science (PLoS)
1 publication, 1.01%
Thieme
1 publication, 1.01%
Cold Spring Harbor Laboratory
1 publication, 1.01%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 1.01%
2
4
6
8
10
12
14
16
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Sehgal P. et al. Systematic review: safety of mesalazine in ulcerative colitis // Alimentary Pharmacology and Therapeutics. 2018. Vol. 47. No. 12. pp. 1597-1609.
GOST all authors (up to 50) Copy
Sehgal P., Colombel J., Aboubakr A., Narula N. Systematic review: safety of mesalazine in ulcerative colitis // Alimentary Pharmacology and Therapeutics. 2018. Vol. 47. No. 12. pp. 1597-1609.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1111/apt.14688
UR - https://doi.org/10.1111/apt.14688
TI - Systematic review: safety of mesalazine in ulcerative colitis
T2 - Alimentary Pharmacology and Therapeutics
AU - Aboubakr, A
AU - Colombel, Jean-Frédéric
AU - Narula, Neeraj
AU - Sehgal, Priya
PY - 2018
DA - 2018/05/03 00:00:00
PB - Wiley
SP - 1597-1609
IS - 12
VL - 47
SN - 0269-2813
SN - 1365-2036
ER -
BibTex |
Cite this
BibTex Copy
@article{2018_Sehgal,
author = {A Aboubakr and Jean-Frédéric Colombel and Neeraj Narula and Priya Sehgal},
title = {Systematic review: safety of mesalazine in ulcerative colitis},
journal = {Alimentary Pharmacology and Therapeutics},
year = {2018},
volume = {47},
publisher = {Wiley},
month = {may},
url = {https://doi.org/10.1111/apt.14688},
number = {12},
pages = {1597--1609},
doi = {10.1111/apt.14688}
}
MLA
Cite this
MLA Copy
Sehgal, Priya, et al. “Systematic review: safety of mesalazine in ulcerative colitis.” Alimentary Pharmacology and Therapeutics, vol. 47, no. 12, May. 2018, pp. 1597-1609. https://doi.org/10.1111/apt.14688.
Found error?